Effect of a butyrophenone derivative, U-32,802A, on brain biogenic amines.
D000818:Animals; D001679:Biogenic Amines / Q000378:metabolism*; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D002090:Butyrophenones / Q000494:pharmacology*; D002250:Carbon Radioisotopes; D003342:Corpus Striatum / Q000378:metabolism; D003514:Cyclohexylamines / Q000494:pharmacology; D003986:Dibenzocycloheptenes / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005464:Fluorobenzenes / Q000494:pharmacology; D006220:Haloperidol / Q000494:pharmacology; D006719:Homovanillic Acid / Q000378:metabolism; D066298:In Vitro Techniques; D008297:Male; D009638:Norepinephrine / Q000037:antagonists & inhibitors / Q000378:metabolism; D011437:Propylamines / Q000494:pharmacology; D012110:Reserpine / Q000494:pharmacology; D012701:Serotonin / Q000378:metabolism; D012702:Serotonin Antagonists; D013154:Spleen / Q000378:metabolism; D013997:Time Factors; D014316:Tritium
D001679:Biogenic Amines; D002090:Butyrophenones; D002250:Carbon Radioisotopes; D003514:Cyclohexylamines; D003986:Dibenzocycloheptenes; D005464:Fluorobenzenes; D011437:Propylamines; D012702:Serotonin Antagonists; D014316:Tritium; D012701:Serotonin; C006296:U-32,802A; D012110:Reserpine; D006220:Haloperidol; D004298:Dopamine; D009638:Norepinephrine; D006719:Homovanillic Acid